Short answer
Keros Therapeutics, Inc. (KROS) filed an 8-K current report with the SEC on September 28, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Phase 2 trial of rinvatercept initiated in Duchenne muscular dystrophy.
Keros Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Phase 2 trial of rinvatercept initiated in Duchenne muscular dystrophy
- First patient dosed on September 28, 2026, marking clinical development advancement
- Exhibit 99.1 contains the company’s supporting press release and trial details
Item EX-99.1 · Exhibit EX-99.1
- First patient dosed in Phase 2 rinvatercept trial for Duchenne muscular dystrophy, advancing Keros’ lead neuromuscular program
- Initial trial data expected in first half of 2027, establishing the next major clinical catalyst
- Open-label, multi-cohort trial focused primarily on safety and tolerability in late-ambulatory and early non-ambulatory patients
- Secondary assessments include pharmacokinetics, anti-drug antibodies, body composition, and skeletal muscle, motor, cardiac, and pulmonary function
- Rinvatercept’s clinical success remains uncertain amid funding, enrollment, competition, manufacturing, and regulatory risks
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Keros Therapeutics, Inc. 8-K filings
Get the next KROS 8-K as it lands
Follow KROS for push alerts, or ask the research agent what this filing means.